The High Cost of Insulin in the United States: An Urgent Call to Action

Rajkumar, S. Vincent

doi:10.1016/j.mayocp.2019.11.013

Cited by 35 publications

(27 citation statements)

References 15 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the case of prescription drugs, we already have major problems controlling price, even before this pandemic. 13 If we fail to take strict measures, access to life-saving medications will be limited by cost, and this will disproportionately affect uninsured people and the elderly d the ones most vulnerable to COVID-19. Making treatment (and vaccines, as they become available) accessible and affordable is therefore critical.…”

Section: Recommendations To Control Costmentioning

confidence: 99%

“…The role PBMs play in contributing to increased prescription drug costs is best illustrated by insulin prices that have increased several fold over the past 10 years even for older insulin preparations. 13 The resulting higher retail prices disproportionately affect uninsured and under-insured people. To prevent these problems, the federal government must prohibit deductibles and rebates for COVID-19especific drugs.…”

Section: Recommendations To Control Costmentioning

confidence: 99%

See 1 more Smart Citation

Medication Shortages During the COVID-19 Crisis

Choo

Rajkumar

2020

Mayo Clinic Proceedings

Self Cite

View full text Add to dashboard Cite

Section: Recommendations To Control Costmentioning

confidence: 99%

Section: Recommendations To Control Costmentioning

confidence: 99%

Medication Shortages During the COVID-19 Crisis

Choo

Rajkumar

2020

Mayo Clinic Proceedings

Self Cite

View full text Add to dashboard Cite

“…106 Limited supplies of drugs used to treat both COVID-19, such as antimicrobials and sedatives, and other life-threatening conditions may trigger costs to rise, 110 as has been seen with insulin. 111 Drug shortages are expected to affect generic drugs, in particular, because of limited FDA-approved generic versions (only 1 or 2) available for sale in the United States. 110 In addition, fewer new drugs for non-COVID-19-related treatment are expected to launch as a consequence of recent pharmaceutical development being focused on the novel coronavirus vaccinations.…”

Section: Pharmaceutical Supply Chainmentioning

confidence: 99%

Return to Work: Managing Employee Population Health During the COVID-19 Pandemic

Fragala

Goldberg

2021

Population Health Management

View full text Add to dashboard Cite

Coronavirus disease-2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has abruptly transformed the outlook of employer health benefits plans for 2020 and 2021. Containing the spread of the virus and facilitating care of those infected have quickly emerged as immediate priorities. Employers have adjusted health benefits coverage to make COVID-19 testing and treatment accessible and remove barriers to care in order to facilitate the containment of the disease. Employers also are introducing strategies focused on testing, surveillance, workplace modifications, and hygiene to keep workforces healthy and workplaces safe. This paper is intended to provide evidence-based perspectives for self-insured employers for managing population health during the COVID-19 pandemic. Such considerations include (1) return to work practices focused on mitigating the spread of COVID-19 through safety practices, testing and surveillance; and (2) anticipating the impact of COVID-19 on health benefits and costs (including adaptations in delivery of care, social and behavioral health needs, and managing interrupted care for chronic conditions).

show abstract

“…Even some old drugs can remain as virtual monopolies. For example, in the United States, three companies, NovoNordisk, Sanofi-Aventis, and Eli Lilly control most of the market for insulin, contributing to high prices and lack of competition 6 .…”

Section: Monopolymentioning

confidence: 99%

“…In such a system, prescription drugs approved in one member country can automatically be granted regulatory approval in the others, greatly simplifying the regulatory process. This requires the type of trust, shared standards, and cooperation that we currently have with visa-free travel and trusted traveler programs 6 .…”

Section: Faster Approval Of Generics and Biosimilarsmentioning

confidence: 99%